Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Study participants who have been clinically diagnosed with Parkinson disease will receive no treatment, treatment with either levodopa, or treatment with Mirapex for a period of 12 weeks. Over the course of the study subjects will travel to the Institute for Neurodegenerative Disorders (IND) in New Haven, Connecticut for brain imaging.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute for Neurodegenerative Disorders
• Collaborators: Boehringer Ingelheim; United States Department of Defense
• Treatments: Levodopa; Pramipexole

Criteria

Inclusion Criteria:

• 30 years or older at time of Parkinson Disease (PD) diagnosis

• clinical diagnosis of PD of equal to or less than 7.5 years

• Normal laboratory screening

Exclusion Criteria:

• Participant is pregnant

• Participant has atypical or drug induced PD

• Participant has significant dementia